This website uses cookies. By using the site you are agreeing to our Privacy Policy.

Top of the page.
Skip the menu to main contents.
Move to main menu.
Skip to main contents.

Main menu starts here.
Skip the main menu to current location in your website.

Current location in your website.
Skip to main contents.

What's New


The information in news releases is current at the time of the release. Note that the information shown here may not be latest information (termination of production or sales, changes to specifications or pricing, organizational or contact address changes, etc.), and may be subject to change without prior notice.

Announcement of the Launch of Geninax® Tablet, an Oral New-Type Quinolone Antibacterial Agent, in Japan
October 4, 2007

Japan, October 4, 2007 - Astellas Pharma Inc. ("Astellas"; Headquarters: Tokyo; President and CEO: Masafumi Nogimori), Taisho Toyama Pharmaceutical Co., Ltd. ("Taisho Toyama"; Headquarters: Tokyo; President: Akira Ohira) and Toyama Chemical Co., Ltd. ("Toyama"; Headquarters: Tokyo; President: Masuji Sugata) today announced that an oral formulation of new-type quinolone antibacterial agent, Geninax® (generic name: garenoxacin mesilate hydrate, a development number: T-3811), will become available in Japan on October 5, 2007.

Garenoxacin, a new type of quinolone discovered by Toyama, has strong activity against respiratory tract infection pathogens and otorhinolaryngological infection pathogens including multi-drug resistant S.pneumoniae. It exhibits good oral absorption and tissue distribution, which allows once-daily oral administration. Geninax® is the first synthetic antibacterial which has the indication for penicillin resistant S. pneumoniae, the premium for usefulness was approved, and higher NHI price was obtained as compared with existing antibacterial agents. Toyama and Taisho Pharmaceutical Co., Ltd. (Headquarters: Tokyo; President: Akira Uehara) have jointly developed Geninax® for the treatment of respiratory infections and otolaryngologic infections in Japan.

Toyama and Astellas have concluded a basic licensing agreement for the sales & marketing and joint development for Geninax® within Japan in March 2006. According to the agreement for Geninax®, Toyama will manufacture the products, and Astellas will distribute the products, which will be co-promoted by Astellas and Taisho Toyama.

Details of Geninax are as follows:
Date of marketing approval : July 31, 2007
Brand name : Geninax® Tablets 200mg
Generic name : Garenoxacin mesilate hydrate(JAN)
Classification : Synthetic antibacterial agent
Indication : <Indicated bacteria>
Garenoxacin-susceptible bacteria: Staphylococcus sp., Streptococcus sp., Streptococcus pneumoniae(including penicillin resistant Streptococcus pneumoniae), Moraxella (Branhamella) catarrhalis, Escherichia coli, Klebsiella sp., Enterobacter sp., Haemophilus influenzae, Legionella pneumophila, Chlamydia pneumoniae and Mycoplasma pneumoniae.
Pharyngitis·laryngitis, Tonsillitis (including peritonsillitis and peritonsillar abscess), Acute bronchitis, Pneumonia, Secondary infection in chronic respiratory lesion, Otitis media, Sinusitis
Dosage and Administration : The usual adult dosage for oral use is 400mg of garenoxacin once daily.
Approval holder : Toyama Chemical Co., Ltd.
Packaging : Tablets 200mg: 100 tablets (PTP), 500 tablets (PTP, Bottle)
NHI reimbursement prices : 296.50 Japanese yen/200mg tablet
Date of NHI price listing : September 21, 2007
Date of launch : October 5, 2007
Footer starts here.

Pages ends here.
Move to top of the page.